Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1201 to 1215 of 2188 results for guidelines

  1. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

  2. Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)

    Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.

  3. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

    Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

  4. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .

  5. Executive team

    Day-to-day decision making is the responsibility of NICE's executive team.

  6. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  7. Guidance on the use of coronary artery stents (TA71)

    Evidence-based recommendations on using coronary artery stents in adults.

  8. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

  9. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (HTG495)

    Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.

  10. GreenLight XPS for treating benign prostatic hyperplasia (HTG650)

    Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.

  11. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (HTG643)

    Evidence-based recommendations on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine in adults. This involves attaching a small device on the forehead to send small electrical currents to the nerves that bring sensation to the upper eyelids, forehead and scalp.

  12. Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease (HTG749)

    Evidence-based recommendations on laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. This involves placing an implant on the outside of the upper part of the stomach wall using keyhole surgery.

  13. Transvaginal mesh repair of anterior or posterior vaginal wall prolapse (HTG456)

    Evidence-based recommendations on transvaginal mesh repair of anterior or posterior vaginal wall prolapse. This involves inserting a mesh to replace tissue that has weakened and caused the pelvic organs to drop down (prolapse) into the vagina.

  14. PulmoVista 500 for monitoring ventilation in critical care (MIB203)

    NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care .

  15. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.